Novel format single-domain antibodies using human VL domain as scaffold

Xingbo Yan1, Ling Chen2, Yuqing Shen3

  • 1Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing 210009, China; Getein Biotechnology Co., Ltd., Nanjing 210000, China.

Single-domain antibodies (sdAbs) represent a unique class of antibody fragments with distinct advantageous characteristics: small monomeric size, excellent solubility and high thermal stability. However, most sdAbs currently available are derived from immunized animals and require humanization for therapeutic use. Notably, sdAbs feature a longer and variable-length third complementarity-determining region (CDR3)-a key structural element for antigen binding but one that increases the technical complexity of library construction. To address these challenges, this study, for the first time, describes the development of synthetic sdAb libraries using a stability-engineered human light-chain variable domain (VL) as the scaffold. We performed limited randomization on three loops located on the opposite side of the CDRs using degenerate codons, which were designed based on the natural length and amino acid properties of these loops. Eukaryotic expression assays confirmed that sdAbs generated via this randomization strategy exhibit excellent secretory expression efficiency. We constructed two ribosome display libraries using two sets of degenerate codon primers and compared the panning efficiency of two strategies against four model antigens (Jo-1, SSB, HAV, and CRP): standalone ribosome display and a combined approach of ribosome display followed by phage pIX display. Both strategies successfully yielded target-specific binders, with the combined panning method demonstrating superior performance to standalone ribosome display. The results demonstrate that synthetic sdAb libraries based on a stability-optimized human VL scaffold provide a facile and reliable source of functional sdAbs. This innovative design is anticipated to serve as a promising platform for the development of next-generation single-domain bispecific antibodies.

Related Concept Videos

Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
68.8K
Antibody Structure01:10

Antibody Structure

15.3K
Conservation of Protein Domains Over Different Proteins02:26

Conservation of Protein Domains Over Different Proteins

Protein domains are small structurally independent units that are part of a single amino acid chain.  Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
15.1K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
10.4K